Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cc-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 0.69 |
| ▸ | PRKDC known ✓ | P78527 | 1/20 | 0.69 |
| ▸ | RPTOR | Q8N122 | 17/20 | 0.69 |
| ▸ | MLST8 | Q9BVC4 | 17/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.69 |
| ▸ | CSF1R | P07333 | 1/20 | 0.69 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-115 SCHEMBL29808653 | 1.00 | MTOR (0.69) | MTORRPTORMLST8PIK3CACSF1R | |
| Cc-115 SCHEMBL14877034 | 1.00 | MTOR (0.69) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL139008 | 0.90 | MTOR (0.59) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL17189817 | 0.88 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL19946393 | 0.87 | MTOR (0.53) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138461 | 0.86 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522076 | 0.86 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL22675179 | 0.84 | MTOR (0.69) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL153831 | 0.84 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL155714 | 0.84 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 899 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| EP-4744665-A1 | COMBINATION OF POLQ INHIBITOR COMPOUND AND ANTI-CANCER THERAPEUTIC AGENT OR RADIOTHERAPY | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| CN-110403943-B | Application of CC-115 in preparation of antifungal drugs and pharmaceutical composition thereof | 陕西科技大学 | 2022-05-17 | — | — | CN | claimed |
| WO-2022076517-A1 | SUBJECT-SPECIFIC TREATMENTS FOR VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| CN-108686221-B | Synergistic antitumor drug | 广州威溶特医药科技有限公司 | 2022-02-22 | — | — | CN | claimed |
| US-20220040180-A1 | KITS AND METHODS FOR TREATING CANCERS | TALON THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PRKDC 1573/4885RPTOR 3/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | MTOR 3/4885PRKDC 179/4885RPTOR 25/4885 |
| US-20220040180-A1 | KITS AND METHODS FOR TREATING CANCERS | KIT, TP53, RNASE1 | MTOR 2989/4885PRKDC 38/4885RPTOR 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.